Phase 4 N=106 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=26 Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Metastatic Renal Cell Carcinoma · Metastatic Melanoma
Primary: Change in the Area Under the Concentration-Time Curve (AUC) From 0 to 8 Hours (AUC0-8) of Aldesleukin After One Cycle of Therapy — 60359.9; 173127.7; -22171.6 hour times…
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 4 N=60 Osimertinib Study in Indian Patients
Non Small Cell Lung Cancer (NSCLC)
Primary: Safety of Osimertinib — 60 Participants
Phase 4 N=1,251 UW Quitting Using Intensive Treatment Study (QUITS)
Tobacco Dependence
Primary: 52-Week Point-Prevalence Abstinence — 74; 79; 78; 76 Participants — p=.66
Phase 4 N=270 Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Multiple Sclerosis
Primary: Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 1 (Month 1-6)…
Phase 4 N=300 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Nicotine Dependence · Major Depressive Disorder
Primary: Bioverified Point-prevalence Abstinence at 27 Weeks — 6; 3; 13; 13 Participants
Phase 4 N=9 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Actinic Keratosis
Primary: Percent Change From Baseline in Lesion Count at Week 18 — 95.5 percent change
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
Phase 4 N=121 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
Multiple Myeloma
Primary: Percentage of Participants With ≥1 SRE at the End of 1 Year on Study — 0; 0.17 percentage of participants
Phase 4 N=6 Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
Paget's Disease of the Bone
Primary: Percentage of Participants With Serum Alkaline Phosphatase Within the Normal Range at Month 6 Last Observation Carried Forward (LOCF) — 83.3 Percentage of Participants
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Phase 4 N=261 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Breast Cancer
Primary: Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia. — 25 Participants
Phase 4 N=109 Response to Anti-hypertensives in Pregnant and Postpartum Patients
Hypertension in Pregnancy · Preeclampsia
Primary: Time to Achieve Non Severe Range Blood Pressure — 10; 20 minutes
Phase 4 N=206 Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Time to PSA Progression With 1st Line AAT (TTPP1) — 21.39; 5.78 Months — p=<0.001